Publications by authors named "A Sverrild"
Chronic obstructive pulmonary disease (COPD) is a progressive, incurable disease associated with smoking and advanced age, ranking as the third leading cause of death worldwide. DNA damage and loss of the central metabolite nicotinamide adenine dinucleotide (NAD) may contribute to both aging and COPD, presenting a potential avenue for interventions. In this randomized, double-blind, placebo-controlled clinical trial, we treated patients with stable COPD (n = 40) with the NAD precursor nicotinamide riboside (NR) for 6 weeks and followed-up 12 weeks later.
View Article and Find Full Text PDFArticle Synopsis
- Abnormal breathlessness during intense exercise can result from several conditions like exercise-induced bronchospasm, laryngeal obstruction, or breathing pattern disorders, often missed in regular tests.
- A retrospective study involved 24 patients, including professional athletes, where advanced testing revealed specific conditions in 66.7% of cases, leading to tailored treatment plans.
- Significant findings included that 38% had exercise-induced laryngeal obstruction, predominantly in younger athletes, and highlighted the need for specialized follow-up and interventions based on individual diagnoses.
Objective: Acute exacerbations (AEs) of asthma are heterogeneous in terms of triggers, outcomes, and treatment response. This study investigated biomarker defined infective and inflammatory AE phenotypes in hospitalized adult asthma patients, and their impact on clinical outcomes and phenotype stability at AE recurrence.
Method: Patients with asthma admitted with an AE between January 2010 and December 2011 with a 3-year follow-up were retrospectively studied.
In the last 30 years, the treatment of obstructive lung diseases, such as asthma and COPD, has seen significant advancements. Introduction of inhaled corticosteroids (ICS) and, more recently, biological treatments has revolutionized care. Biological treatments are very successful in severe asthma and are expected to be approved for COPD soon.
View Article and Find Full Text PDF